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New findings 
 What is the topic for this review? 
The dichotomisation of continuous-level physiological measurements into 
“responders” and “non-responders”, when interventions/treatments are examined in 
robust parallel-group studies 
 What advances does it highlight? 
Sample responder counts are biased by pre-to-post within-subjects variability. 
Sample differences in counts may be explained wholly by differences in mean 
response, even without individual response heterogeneity, and even if test-retest 
measurement error informs the choice of response threshold. A less biased and 
more informative approach employs the SD of individual responses to estimate the 
chance a new person from the population of interest will be a responder.  
 
Abstract 
As a follow-up to our 2015 review, we cover more issues on the topic of “response 
heterogeneity”, which we define as clinically-important individual differences in the 
physiological responses to the same treatment or intervention that cannot be attributed to 
random within-subjects variability. We highlight various pitfalls with the common practice of 
counting the number of “responders”, “non-responders” and “adverse responders” in 
samples that have been given certain treatments/interventions for research purposes. We 
focus on the classical parallel-group randomised controlled trial (RCT) and assume typical 
good practice in trial design. 
We show that sample responder counts are biased because individuals differ in terms of pre-
to-post within-subjects random variability in the study outcome(s) and not necessarily 
treatment response. Ironically, sample differences in responder counts may be explained 
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wholly by sample differences in mean response, even if there is no response heterogeneity 
at all. Sample comparisons of responder counts also have relatively low statistical precision. 
These problems do not depend on how the response threshold has been selected, e.g. on 
the basis of a measurement error statistic, and are not rectified fully by the use of confidence 
intervals for individual responses in the sample. 
The dichotomisation of individual responses in a research sample is fraught with pitfalls. 
Less biased approaches for estimating the proportion of responders in a population of 
interest are now available. Importantly, these approaches are based on the standard 
deviation for true individual responses, directly incorporating information from the control 
group.  
 
Keywords: Response heterogeneity, Inter-individual differences, standard deviation, 
responders, within-subject random variability 
  
 
This article is protected by copyright. All rights reserved.4 
1. Introduction and Background 
In a previous issue of Experimental Physiology, the paper, “True and false individual 
differences in the physiological response to an intervention” was published (Atkinson and 
Batterham, 2015). This earlier review was written because we observed that many claims of 
individual differences in the physiological responses to exercise training and other 
interventions were based solely on intervention group data, sometimes even if these data 
were collected as part of a parallel arm randomised controlled trial (RCT). In the context of 
personalised (precision) medicine, we showed how common plots and analyses of pre-to-
post changes (measured on a continuous scale) can be misleading when undertaken only 
on data from the intervention/treatment group because of unavoidable within‐subject random 
variation between the baseline and follow-up time-points. This source of variation is 
inevitable even with „gold‐standard‟ measurement tools/protocols that happen to have 
excellent short-term (over hours or days) repeatability. For example, the short term test-
retest coefficient of variation (CV) of body mass is probably less than 0.5%, but the pre-to-
post CV in body mass over a 6-12 month period (a typical intervention duration for a weight 
management service) will be considerably larger (Abe et al., 2019; Atkinson and Batterham, 
2017). This differential amount of variability, depending on duration of retest (follow-up) is 
likely to be present for most physiological measurements and functional tests (Abe et al., 
2019). We showed that this component of variance between baseline and follow-up may be 
so substantial that it can sometimes explain all the perceived individual response 
differences, as observed solely in the treatment/intervention group (Atkinson and Batterham, 
2015). 
In our previous review, we presented a “roadmap” for research (particularly RCTs) on 
physiological response heterogeneity, which included how to quantify individual response 
differences via a relatively simple comparison of the standard deviation (SD) of changes 
(baseline – follow-up values) between intervention and comparator arms in a parallel group 
study. We termed this difference between SDs of change in intervention and control groups 
the standard deviation for individual responses (SDir). Any substantial treatment effect 
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heterogeneity that is larger than the heterogeneity in the data due to random within-subject 
variability over time would be revealed if the SD of changes in the treatment group is larger 
than that in the comparator group (Hopkins, 2015; Atkinson and Batterham, 2015; Cortes et 
al., 2018; Atkinson et al., 2018). When these SDs are similar, any individual response 
differences to the treatment itself are not large enough to be detected beyond the typical and 
inevitable within-subjects random variability in the study outcome. Therefore, further 
analyses, e.g. identification of specific response moderators, may be unwarranted and 
wasteful of resources. In essence, this reflects the “counterfactual” nature of the control 
group, which must always be appreciated in parallel group trials, whether one is researching 
mean or individual treatment effects (Senn, 2015; 2018). 
In Panel 1, we present various questions which have been raised in conferences and 
communications about the SDir approach since our last publication, and we have 
endeavoured to answer these questions. Like the estimation of mean treatment effects, any 
SD of changes comparison is contingent on a well-designed, adequately powered and 
executed RCT. We preferred to interpret the SDir against a minimal clinically important 
difference (MCID), while retaining the original units of measurement. Recently, Cortes et al. 
(2018) compared the SD of changes using a “relative” and unit-free F-ratio (treatment SD / 
control SD) approach. Both approaches could be reported in any RCT. 
Another practice that is common in research of this nature is counting the number (or 
proportion) of people in the study sample(s) who show observed responses above 
(responders) or below (non-responders) certain thresholds. In this, our update paper, we 
focus on the question of how robust the various responder identification type approaches are 
in physiological research. We maintain that there are also many pitfalls in these approaches, 
the worst scenario being that true clinically-important response heterogeneity has not been 
quantified and the responder counting analyses are not robust, leading to false inferences 
and recommendations about individuals who are deemed to be responders/non-responders 
in a given sample. Our primary aim, in this update review, is, therefore, to highlight these 
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pitfalls about sample responder counting and make recommendations on how to avoid these 
pitfalls.  
2. A definition of response heterogeneity in the context of precision medicine 
As in our previous review, we focus on a definition of response heterogeneity that is relevant 
to study variables (outcomes) measured on a continuous scale and that is most relevant to 
precision (personalised) medicine. We highlight the fact that the response heterogeneity we 
cover here is distinct from other aspects of personalised medicine, e.g. a personal risk 
profile, based on genes or other information, to predict future conditions or diseases. So, by 
“treatment response heterogeneity”, we refer to clinically important individual differences in 
the magnitude of response to the same treatment/intervention. We use these latter terms 
interchangeably. We refer to individual differences in treatment response that are not 
explained by random within-subject variability over time. We also emphasise that this 
definition refers to the responses to the same treatment prescribed to a sample of 
individuals, rather than observing how many people in different samples respond to different 
interventions beyond a certain threshold response value. We discuss later, and in more 
detail, how this latter approach tells us little about true response heterogeneity in the context 
of personalised or precision medicine. 
By “clinically important”, we mean a magnitude of response that, ideally, is anchored to a 
meaningful change in the risk of morbidity and/or mortality, or an overall endpoint that 
matters like the chance of winning an Olympic medal in an exercise science context. There 
are various ways in which “target differences” or minimal clinically important differences 
(MCID) can be arrived at, and we encourage readers to refer to the guidelines laid down in 
the DELTA1 and DELTA2 publications (Cook et al., 2014; 2018). Later, we also highlight the 
difference between this MCID and “minimal detectable change”, which is the magnitude of 
response that surpasses, with a certain probability, measurement error. Such a change may 
be “statistically significant” or be detectable amongst a background of experimental noise, 
but it may not necessarily be clinically important and be the same as the MCID (de Vet et al., 
2006). 
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3. How large should the mean treatment response be for response heterogeneity to 
matter? 
In our previously-reported “roadmap”, we showed how the SDir (derived from the standard 
deviations of change for both intervention and control groups) can be used to inform the 
magnitude of response heterogeneity that is adjusted for any within-subjects random 
variability (present in both treatment and control groups). The SDir is compared to a target 
clinically-important threshold, alongside the magnitude of mean treatment effect. One 
question within this approach is how likely is it that response heterogeneity is clinically 
important, if the mean intervention effect is already known to be close to zero?  
Harrell (2018) maintained that, if response heterogeneity is present when the mean 
treatment effect is tiny, it follows that there must be patients or subgroups for whom the 
treatment worsens the outcome. Harrell (2018) thought it not to make sense to perform 
further studies on a treatment known to be, on average, not beneficial at all just to gain 
further knowledge that the treatment could actually also be detrimental to some people. In 
the context of exercise training, this notion would translate to a researcher wanting to find 
out whether a certain training intervention worsens health for some people, even though it is 
already known that the intervention has close to a zero average effect.  
In theory, if a certain intervention leads to a clinically important benefit on average, and there 
is actually very little response heterogeneity, then this is preferable to the situation where 
response heterogeneity is present but only relatively few people will benefit from the 
intervention. Such interpretations of response heterogeneity, especially in the context of 
health economics, have been reported to be under-appreciated (Senn, 2015; 2018). 
Nevertheless, if the mean treatment response is small but response heterogeneity between 
people is indeed very large, then we believe that this finding is important to confirm robustly, 
as the treatment could benefit a reasonably large proportion of people in the population of 
interest. Therefore, we think it is interesting to know what proportion of people in a 
population of interest may be responders, non-responders or adverse responders. 
Nevertheless, there does not seem to be, at present, any agreed thresholds for these 
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proportions in order to guide research and practice, e.g. whether a certain treatment is worth 
rolling out if the estimated proportion of responders is say 20%.  
4. A hypothetical study and dataset 
In keeping with our previous review, we can communicate some pitfalls and issues via a 
hypothetical RCT and a data simulation involving large (n=1000) samples. This is not a 
simulation that is designed to illustrate the impact of sampling error on a certain statistic. We 
merely aim to scrutinise various responder counting approaches in hypothetical large 
samples with characteristics we can stipulate a priori. In this respect, we generated our 
samples using the popular package, Microsoft Excel, rather than dedicated code-dependent 
software such as R, with the belief that any researcher may like to reproduce, or formulate 
their own, data simulation. The overall benefits of this approach are that we know exactly 
what the parameters of the data are, e.g. Normal distribution of pre-to-post changes, we can 
pre-specify means and SDs that are realistic, and we can make inferences with decent 
precision with a sample size of 1000 (Morris et al., 2019). 
Obviously, all the usual pre-specified trial design and data analysis considerations are 
critical, whether it is treatment response heterogeneity that is of interest and/or the mean 
treatment response. Both these outcomes are reliant on good trial design. These issues are 
covered comprehensively in the CONSORT explanation and elaboration document (Moher 
et al., 2010). If there are deviations from typical good practice in trial design (Moher et al., 
2010), then the least of the researchers problems is how to robustly undertake a response 
variance comparison, or indeed any data analysis (Panel 1). No statistical analysis 
approach, whether it is designed to quantify mean treatment response or response 
heterogeneity, can retrieve poor study design characteristics (Campbell and Machin, 1993).  
In Table 1, we present the results of the data simulation for a three-group parallel arm 
intervention study designed to quantify the effects of two exercise interventions vs a control 
group on maximal oxygen uptake (VO2max). This design and context is similar to those 
reported recently by Williams et al. (2019). The three study groups are; control (zero change 
in true VO2max for all participants), Intervention 1 (a 3.6 ml/kg/min increase in true VO2max 
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for all participants) and Intervention 2 (a 2.0 ml/kg/min increase in true VO2max for all 
participants). We highlight the fact that the true change in VO2max is a constant value for 
every hypothetical participant, and only varies according to the study group they are in. In 
this way, we wish to set up the “null position” of no true treatment response heterogeneity. In 
this situation, it follows that there are no responders whatsoever in a sample when the mean 
response is below the response threshold. Later, we discuss the basis of how such a 
threshold should be selected. 
Within-subjects random measurement variability is inevitable in physiological research. 
Therefore, a random amount of within-subjects variability was added to each of the “true 
values” and this “error” had an approximate mean (SD) of 0 (3) ml/kg/min in order to provide 
each group‟s observed baseline and follow-up measurements. These errors led to the SD of 
change in each study arm to be 4.3-4.4 ml/kg/min, which are similar to the SDs of change 
reported by Prud‟Homme et al. (1984). These values of SDchange are expected because of 
the mathematical relationship between the SD of change and the within-subjects SD or 
“typical error”, e.g. SD of change = within-subjects SD x √2 (Atkinson and Nevill, 1996).  As 
is likely the case for real data, we assumed that the distribution of these within-subjects 
errors is Gaussian. Most measurement error statistics are reliant on this assumption 
(Atkinson and Nevill, 1996), which should, nevertheless, always be verified for any data 
analysis. Interestingly, non-Gaussian distribution of responses has been claimed for certain 
measurements of pain (BMJ, 2019), although whether this is the case in general has not yet 
been confirmed for studies on pain outcomes. Irrespective of this assumption, we highlight 
the fact that individuals can differ in how much random within-subjects variability influence 
the measurements made at baseline and follow-up timepoints, as is the case for real data. 
That is, in any study, some participants show higher amounts of random test-retest variability 
than other participants. This common measurement characteristic is important for explaining 
some of our observations and conclusions later in this review. The Excel spreadsheet for 
these data is available as a supplementary file. 
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Mean intervention effects in RCTs are most-appropriately quantified with a general linear 
model, including study group as a fixed factor and baseline VO2max as a covariate. This 
ANCOVA-model approach has been shown to be superior to a group x time interaction 
based model (Vickers, 2005), which is unfortunately often selected by physiologists and 
exercise scientists The estimated mean (95% confidence interval) change in VO2max (vs 
control) for interventions 1 and 2 are 3.6 (3.2 to 4.0) ml/kg/min and 2.2 (1.8 to 2.6) ml/kg/min, 
respectively. These are conditional mean changes, whereby group differences at baseline 
have been adjusted for in the model. The same baseline-adjusted modelling approach can 
be used to also derive the SDir (see later). 
5. Counting responders and non-responders in the sample using a defined response 
threshold 
The fundamental problem with sample responder counting in a parallel arm RCT is the 
“counterfactual”, whereby it is impossible to determine who is a responder in a treatment 
arm, because it is unknown what would have happened to that individual if, contrary to the 
fact, they had been in the control group (Senn, 2015). Consequently, there are four issues of 
practical validity to consider when counting the number of changes in a sample that surpass 
or fall short of a certain response threshold and comparing these counts between different 
study groups who received different interventions, 
(i) The relevance of this approach to response heterogeneity in the context of 
precision medicine, 
(ii) The sensitivity of the responder counts to group differences in mean response, 
(iii) The incorporation of probability inference for the precision of identifying 
responders or non-responders, and what is done with this information. 
(iv) How the response threshold has been selected.  
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5.1. What are responder counts in samples actually telling us? 
We will consider issues (i) and (ii) together, since we maintain that the sensitivity of the 
responder counting approach to the group mean change renders the approach irrelevant to 
response heterogeneity in the context of precision medicine. Note, in Table 1, that the SDs 
of observed changes are very similar (4.3-4.4 ml/kg/min) for all three groups, in agreement 
with the fact that no individual differences in change were simulated in all three groups. 
According to our previously-reported equation to estimate the SD for true individual response 
heterogeneity, this SD (95%CI) is 0.83 (-1.29 to 1.75) ml/kg/min and 0.41 (-1.47 to 1.58) 
ml/kg/min for Intervention 1 and 2 participants, respectively (observed response 
heterogeneity = random within-subject heterogeneity in the control sample). As mentioned 
above, these SDir estimates and confidence intervals can also be obtained using a 
modelling approach, adjusting for any differences at baseline (Atkinson and Batterham, 
2015). In the case of our large sample random data simulation, the SDir estimates are 
similar between equation and modelling approach. Importantly, the SDir values are small 
and, therefore, not indicative of any clinically important response heterogeneity. This is, of 
course, exactly what was simulated. These SDir values are not exactly zero because of 
sampling error (even for our relatively large sample sizes of 1000 in each group) and small 
random variability in the random number generator in Excel. Note also that, because of the 
sampling error we discussed in section 1, the lower confidence limit for both SDs is negative 
in sign. It can be seen that even with relatively large sample sizes of 1000 cases in each 
study arm, sampling error is still large enough for the 95% confidence interval of a very small 
SDir to overlap zero. 
Strikingly, the responder counts indicate that there are a number of responders and adverse 
responders in each sample, even in the control group. Nevertheless, we already know that 
the treatment response per se of every case is a constant value in each group and smaller 
than the response threshold we selected of 5 ml/kg/min. For example, the “error-free” 
increase for all cases in the Intervention 1 sample is 3.6 ml/kg/min. Nevertheless, the 
responder counts are telling us that 363 (36%) of this sample responded ≥ 5 ml/kg/min. This 
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discrepancy between observed counts and the true counts is due to the inevitable random 
within-subjects variability between the baseline and follow-up time points in the RCT. The 
distribution of this random variability tends to be Normal. Therefore, there are always some 
people who show larger amounts of this variability than other people. In our data simulation, 
the apparent “responders” are actually the cases who happen to show a relatively large 
amount of random variability between baseline and follow-up, and this variability happens to 
be in a positive direction, thus rendering the baseline to follow-up change large and positive. 
The apparent “adverse responders” are cases for which random variability happens to be 
large in the other direction, rendering a substantial apparent deterioration in VO2max. 
Counting the number of responders in a sample is compromised by within-subjects variation 
between time points (and individual differences in this within-subjects variation) and can be 
misleading. One may think that comparing responder counts between intervention and 
control groups would rectify this problem. Nevertheless, this is not the case because there 
can be problems also with such a comparison, and these are covered in the next section. 
5.2. Comparing responder counts between samples. 
Note in Table 1 and Figure 1 how the group differences in observed mean response lead to 
group differences in the observed numbers of responders, adverse responders, and trivial 
responders (according to a response threshold of 5 ml/kg/min and an adverse response 
threshold of -5 ml/kg/min). Therefore, although researchers have made inferences relating to 
response heterogeneity or “trainability” on the basis of such “responder counts” (Ross et al., 
2015; Williams et al., 2019; Hammond et al., 2019; Bonafiglia et al., 2019), it is in fact the 
group differences in mean treatment response that explain the differences in responder 
counts between our groups (Figure 1), besides the fact that the responder counts cannot be 
correct in the first place. Therefore, such group comparisons of responder counts do not 
provide much information about response heterogeneity, as defined in the context of 
precision medicine (section 2).  
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We have demonstrated that responder counts can differ between groups even if there is no 
treatment response heterogeneity present at all within each of the groups. The only factor 
we have manipulated in our simulation is the sample mean. It is incongruous for a proposed 
approach to quantifying individual differences in response to merely reflect differences in 
mean response. Interestingly, this distinction is an important aspect of the work of Geoffrey 
Rose, especially in how population mean characteristics underpin individual characteristics 
in public health (Rose, 2001). Ironically, these responder count comparisons could be telling 
us more about “average medicine” than personalised medicine. Another secondary problem 
with comparing responder counts between samples is the relatively low statistical precision 
or “power” of the comparison. This issue has been covered extensively by Snapinn and 
Jiang (2007).  
5.3. Does the use of a measurement error statistic to inform the response threshold 
help? 
It is clear that the approach of responder counting is compromised by within-subjects 
random variability and group differences in mean response. One question is whether this is 
so, irrespective of how a certain response threshold is formulated, i.e., whether it was 
formulated on the basis of a well-defined minimal clinically important response or in 
comparison to a measurement error statistic like the technical error of measurement, or a 
combination of both the MCID and a measurement error threshold. We selected a response 
threshold of 5 ml/kg/min merely for illustrative purposes knowing that all “error-free” 
responses in both treatment arms are below this MCID. A response threshold should be 
selected on the basis of clinical importance rather than measurement variability (Cook et al., 
2014; 2018). Nevertheless, suppose we select 2 x the “typical error” as our threshold, as 
several authors have done (Ross et al., 2015). Using the information from our control group, 
we can calculate typical baseline to follow-up variability by dividing the SD of changes by the 
square root of 2, giving a typical error of about 3 ml/kg/min. Two times this value gives 6 
ml/kg/min. The proportion of “responders” in each group whose change in VO2max exceeds 
this threshold is 7%, 29% and 19% for control, intervention 1 and intervention 2, 
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respectively. Again, there is a suggestion of “responders” within each sample, when in fact 
there are no cases which exceed a treatment response per se of 6 ml/kg/min in all three 
samples. Moreover, the differences in responder counts are due almost solely to the 
differences in mean response between the groups. The responder count differences are not 
an indication that response heterogeneity differs between the groups, even though the 
response threshold was selected on the basis of a random within-subjects test-retest or 
baseline to follow-up statistic. 
Whatever the threshold value is, and however it is selected, this would not alter the fact that 
it is the group differences in mean response, and not response heterogeneity, which are 
explaining the group differences in “responder counts” in our simulation. This relationship 
between the difference between two group means and the difference in area under the 
Normal curve of changes is well known, has mathematical underpinnings, and can be shown 
by inputting values in to this useful on-line calculator, 
http://onlinestatbook.com/2/calculators/normal_dist.html. For example, if a mean of -0.11 
ml/kg/min and an SD of change of 4.3 are entered into the calculator and the area under the 
Normal curve (AUC) above the threshold of 5 ml/kg/min is calculated, this AUC is 12%, 
which agrees reasonably well with the 13% in our simulated control group (Figure 1). If the 
mean is altered to the 3.6 ml/min/kg and SD = 4.4 ml/kg/min observed for the Intervention 1 
group, then the AUC above 5 ml/kg/min becomes 38%, which, again, agrees well with our 
simulation results (Table 1, Figure 1).  
We maintain that the dependency of responder count comparisons on group differences in 
mean change is not fully appreciated by researchers, even though it is clearly illogical for 
inferences on individual response heterogeneity (in the context of precision medicine) to be 
made entirely on the basis of the magnitude of group mean response. For example, Ross et 
al. (2015) studied what they claimed was the “individual cardiorespiratory fitness response” 
to different types of exercise interventions (undertaken by different groups). The number of 
“responders” was found to increase as the group mean response increased. This approach 
to responder counting has also been adopted by researchers who defined their study topic 
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as “trainability” (Williams et al., 2019). Most definitions of this term encompass the notion 
that individuals differ in their response to the same or similar interventions. Therefore, it is 
unclear how this approach to responder counting relates to this primary question of interest. 
We repeat; observing more individual changes in a sample that surpass a certain response 
threshold when the mean change of that sample is higher has very little to do with individual 
response heterogeneity in the context of precision medicine. 
5.4. Quantifying the probability of being a responder/non-responder in the sample of 
interest 
Approaches have been developed for quantifying the probability that a particular person in 
the sample of interest is a responder or non-responder (or a “trivial responder”). The context 
of our review is research and, particularly, an RCT in which parallel samples of participants 
are measured on a particular study outcome at baseline and at a later follow-up time-point. 
This context is not the same as clinical decision making on individual patients nor when 
monitoring individual or team athletes. Therefore, if responders and non-responders can be 
identified in a particular study, it is important for the researcher to communicate exactly what 
will be done with this information, especially with governance and ethics in mind (Harriss et 
al., 2017). According, to the UK Health Research Association (Health Research Authority, 
2018), any information communicated to participants about their research results should be 
in line with the arrangements agreed by the original ethics committee that approved the 
study. This means that full details about how the researcher feeds back information and 
advice to a non-responder or adverse responder should be transparent in the ethics 
approval process and be present on any participant information sheet. 
Bonafiglia et al. (2019) cited the paper by Swinton et al. (2018) in order to attach a 
probability interval around each participant‟s response in the intervention sample itself. For 
example, assuming a large sample, Swinton et al, (2018) reported that an interval of 95% 
width is calculated by response ± SDchange for control x 1.96. This 1.96 multiplier can be 
replaced by values from the t distribution for smaller sample sizes. In Table 2, we show the 
results of applying the similar approach reported by Bonafiglia et al. (2019) to our simulated 
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data. In keeping with their approach, we set the response threshold to 1 MET (3.5 
ml/kg/min). Each individual response interval was calculated according to the equation 
presented by Bonafiglia et al. (2019), whereby Individual 95% CI = Response estimate ± 
(1.96 × TE), The typical error term (TE) is SDchange in the control group divided by √2 = 
4.32/√2 = 3.06. Note that TE itself was used by Bonafglia et al. (2019) rather than the 
SDchange advised by Swinton et al. (2018). Nevertheless, in each study group, we counted 
the number of responders, “uncertain responders”, and adverse responders on the basis of 
each individual‟s whole confidence interval being higher, overlapping or lower than the 
response threshold.  
We can compare the responder counts presented in Table 2 with what we would be 
expecting already knowing the exact nature of our simulated data. For example, we already 
know that the mean treatment effect for intervention 1 is 3.6 ml/kg/min and there that is no 
individual heterogeneity in treatment response in this study group. When the response 
threshold is selected to be 3.5 ml/kg/min, we would, therefore expect about 50% of the 
intervention 1 participants to be above this threshold and 50% of the sample responses to be 
below this threshold. This is because the threshold is close to the mean treatment effect. 
Nevertheless, we do not observe these expected counts because in Table 2, only about 8% 
of the participants have a response that is above 3.5%, according to the approach reported 
by Bonafiglia et al. (2019). This approach is clearly erroneous for the robust identification of 
responders and non-responders.  
Unfortunately, the approach reported by Bonafiglia et al. (2019) is also sensitive to group 
differences in mean response, which compromises its usefulness for indicating response 
heterogeneity or group differences in response heterogeneity. The fact is that only the mean 
treatment effect differs between groups in our simulation. Again, when a mean treatment 
effect is different between samples, then naturally so is the number of people in each sample 
whose response is higher or lower than a certain threshold value, and this is also the case 
here when individual confidence bands are estimated for each individual response.  
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5.5. Sample response “dichotomania” 
There are some other important factors to consider when a researcher is interested in using 
response thresholds on ratio or interval data, to categorise sample participants as 
responders or non-responders. Most importantly, the act of converting measurements on a 
continuous ratio or interval scale into a binary (response/no response) variable has received 
much criticism amongst statisticians, some of whom have labelled this procedure as 
“dichotomania” (Senn, 2005). Besides the issue of poorer statistical power for 
dichotomisation vs analysis of the original continuous data, dichotomisation leads to 
problems in adjusting for baseline differences between study groups. Senn (2005) also 
showed how some responder threshold definitions lead to illogical and inconsistent labelling 
of a “responder”, especially if these definitions are based on multiple outcomes, e.g. both 
systolic and diastolic blood pressures, and are dependent on the initial status of the 
outcome, e.g. being in a higher hypertensive category than a lower category and/or using a 
percentage change as the response threshold. 
Lastly, if one is interested in designing studies to inform precision medicine in general, one 
needs to question the efficiency and utility of identifying responders and/or non-responders 
merely in the study sample, even if this identification process was robust. For example, if 4 
people (10%) from a sample of 40 people who received a certain exercise intervention were 
found to be “non-responders”, is the researcher obliged to undertake further studies on these 
4 people to see what does “work” for them? Such an approach could be very costly relative 
to the scope of the research impact. In this respect, we believe that researchers seem to be 
confusing empirical trials of effectiveness in a research context with exercise performance 
support work, e.g. sports science support or coaching. Again, the most relevant question in a 
research context is not necessarily which individuals in a sample itself are responders/non-
responders, but what are the chances a new person from the population of interest is a 
responder or a non-responder, that is, statistical inference, and not necessarily participant 
identification in the particular study sample itself. 
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6. Estimating the proportion of responders in a population of interest. 
From the arguments presented above, we maintain that identifying people from observed 
values in a single or multiple intervention sample as “responders” or “non-responders” is 
fraught with pitfalls, Although there are approaches for observing individual change for a 
person in an intervention/treatment sample and estimating confidence intervals for their 
“true” individual change, we have shown that the observed change itself can be 
contaminated by within-person random variability between baseline and follow-up 
measurements. Also, we do not think that robust conclusions can be derived by comparing 
responder or non-responder counts between different samples because such comparisons 
lack statistical power and may merely be proxies for sample differences in mean response 
(Senn, 2005; 2015; 2018; Snappin and Jang, 2007). We, therefore, favour approaches that 
do not involve the identification of responders or non-responders in the particular sample(s) 
of interest, but estimate the proportion of responders or non-responders in the population of 
interest. An analogous estimation would be the chance that any new person from the 
population of interest would be a responder or not.  
We maintain that an estimation of how many people in a population of interest who may 
benefit or not from an intervention can be useful. Approaches for this notion have been 
forwarded recently by Swinton et al. (2018) and Hopkins (2018). Importantly, these 
approaches involve the SDir, directly accounting for the random within-subjects variability 
that is present. Essentially, this SDir is considered a parameter for the distribution of true 
responses in the population of interest alongside the mean treatment effect (Figure 2). Then 
the proportion of people predicted to be above or below a certain response threshold is 
estimated using the characteristics of the Normal distribution. Again, there are online 
calculators for this step like the one we mentioned in section 5.3, as well as dedicated 
spreadsheets (Swinton et al., 2018). Only with this approach, does one get close to what 
was actually defined in our simulated datasets (Table 3). For example, the mean treatment 
response for intervention 1 is 3.6 ml/kg/min. Let us assume an MCID of 3.5 ml/kg/min 
(Bonafiglia et al., 2019). Because the mean intervention response is very similar to the 
 
This article is protected by copyright. All rights reserved.19 
selected MCID of 3.5 ml/kg/min, and because the SD for true individual response differences 
is small (0.83 ml/kg/min), it is not surprising that just over half (55%) of all people in the 
population are estimated to be responders and 45% are trivial responders, with no adverse 
responders present. For intervention 2, the SD for true individual responses is 0.41 
ml/kg/min and the mean treatment effect is 2.2 ml/kg/min. Therefore the number of 
responders in the population of interest above an MCID of 3.5 ml/kg/min is estimated to be 
zero for intervention 2, with zero people being lower than the adverse response threshold of 
-3.5 ml/min. Therefore, everyone‟s (100%) response in the population of interest is expected 
to be trivial for intervention 2. This is of course what we simulated; a mean intervention 
response of approximately 2 ml/kg/min and no individual differences in response. 
Hopkins (2018) suggested a similar approach to that of Swinton et al. (2018). Confidence 
intervals for these proportions are best derived using bootstrapping (Swinton et al., 2018), 
preferably the bias-corrected and accelerated bootstrap. However, bootstrapping the whole 
analytical process involving such a relatively complex linear mixed model incorporating 
baseline values of the outcome and perhaps other covariates can be computer-intensive for 
this standard deviation estimation problem. Analytic formulae are available (Mathur  and 
VanderWeele, 2019), but are not robust when the proportion is <0.15 or >0.85. Note that 
these formulae were derived for application to meta-analyses, but are directly transferable to 
deriving confidence intervals for proportions of individual responders, rather than proportions 
of individual studies. We maintain that only these approaches, which use the SDir, give 
estimated population proportions that are relatively unbiased. 
Summary 
We have followed up our earlier review on this research topic by highlighting some additional 
pitfalls in the analysis of individual physiological responses to an intervention or treatment. 
We have focussed particularly on the act of counting the participants in a study group whose 
individual response is above or below a certain response threshold deemed to be important. 
Before doing this, researchers need to ask themselves the following sets of questions; 
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1. What is the goal in identifying research participants as responders, non-responders, 
or adverse responders? Are these people to be followed up with further study? Who 
will fund such studies? How should this information be fed back to participants and 
what will the participants‟ likely reactions be? 
2. What is the response threshold that is clinically or practically important? Given that 
such a threshold might not coincide with the minimal detectable change (as indicated 
by a measurement error statistics), how should this threshold be rationalised? Can a 
response threshold be formulated in relation to a robust anchor of morbidity and/or 
mortality or can it be rationalised on the basis of the fraction of a between-subjects 
standard deviation?  
Once a researcher is comfortable that these questions have been answered, we recommend 
that the approaches of Swinton et al. (2018) and Hopkins et al. (2018) are followed because 
these approaches use the SDir and infer to a population of interest rather than the study 
sample participants. Importantly, the approaches by Swinton et al. (2018) and Hopkins 
(2018) were the only ones that fully reflected the underlying characteristics of our data 
simulations. The approaches based on counting responders in each sample of interest are 
biased relative to the “truth” of our simulation. This bias is not resolved by selecting a 
response threshold based on measurement error or by calculating confidence intervals for 
individual response values. 
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Figure 1. The distributions of individual changes for each of the three simulated study 
samples, together with the proportion of “responders”, “trivial responders” and 
“adverse responders” in each sample. The MCID was an improvement in VO2 peak 
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Figure 2. The hypothetical distribution of responses (free from random within-
subjects variability) for a population of interest (Hopkins 2018). SDir = the SD for 
individual response heterogeneity. The net mean change is the baseline-adjusted and 
control group adjusted mean treatment effect for the sample. P = proportion of the 
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Panel 1. Questions and Answers about between-group response variance 
comparisons and the SDir 
 
1. How should a negative SDir be interpreted? 
A negative sample SDir could result from several isolated factors or a combination of a 
number of factors in a similar way to a sample mean treatment effect that is negative (larger 
change in control group than in intervention group). First the population SDir may be 
negative. The confidence interval for the SDir will be informative in this respect, especially if 
the upper confidence limit itself is also negative. Nevertheless, the most likely explanation for 
a negative SDir is sampling error combined with a population SDir that is small. Again, the 
confidence interval for the SDIr will be informative here. Just as these underlying factors do 
not necessarily compromise the calculation of a mean treatment effect, these explanations 
also do not compromise the calculation of the SDir. 
 
2. What if there are systematic changes in the mean for the control group? 
A population change in the control group due to, for example, learning effects does not affect 
the SD of change in the control group. This fact is inherent in the mathematical 
underpinnings of the SD. Nevertheless, such a systematic mean change in the control group 
is important for a robust estimate of the mean treatment response (intervention mean 
change – control mean change). Recently, Hammond et al. (2019) speculated that the SD of 
change comparison approach is “questionable” when “the control group is contaminated with 
other sources of variability, beyond that of which is random”. This statement denotes a lack 
of appreciation of the difference between systematic and random sources of variance. For 
example, if we added 1 ml/kg/min to all the true follow-up values in our control group, the SD 
of change would be unaffected, and this will always be so because of the term; (sample 
mean – observed value) within the equation for the standard deviation. This is why the 
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random variability we refer to is often also termed “residual” variance, meaning the random 
variation that is leftover once any systematic sources of change have been partitioned. This 
appreciation of how a systematic constant does not affect the variance is “Rule 2” for the 
variance, which is covered at: http://www.kaspercpa.com/statisticalreview.htm  
 
3. How would poor trial design affect the SDir?  
Just as any analysis of mean treatment response does not rectify a poor design, then any 
analysis of response heterogeneity cannot retrieve a poorly designed RCT. Researchers 
should endeavour to design, analyse and report their RCTs in accordance with best practice 
guidelines like CONSORT (Moher et al., 2010). 
 
4. How would loss of participants to follow-up affect the SDir? 
Loss of data at follow-up is a common problem in randomised controlled trials, but there are 
principled approaches for dealing with this problem (Bell et al., 2014; White et al., 2005; 
2011). Any partially missing data (for outcome or covariates), or participant withdrawal 
between baseline and follow-up, should be considered carefully. Such loss of data does not 
necessarily compromise a trial – again, irrespective of whether the mean response or 
response heterogeneity is of primary interest (Panel 1). The extent of any resulting problems 
would depend, in part, on the missing data mechanism. There is no reason to believe that 
data assumed to be missing at random would bias the estimate of a standard deviation of 
change in the exploration of response heterogeneity (Newman and Sin, 2009). The variance 
of change is the statistic used in the calculation of the SDir and the variance is not biased by 
sample size (Zar, 1999). It is good practice to pre-specify a principled approach to 
addressing missing data in the statistical analysis plan for the trial (see e.g., Belle et al., 





This article is protected by copyright. All rights reserved.29 
Table 1. Various mean (SD) measurements for the three parallel groups in the 
hypothetical study. In each group, there are no individual differences in response, merely 
differences between groups in the constant change value for each participant, plus random 
amounts of within-subjects variability between baseline and follow-up. Control = 0 change, 
Intervention 1 = 3.6 ml/kg/min change, Intervention 2 = 2.0 ml/kg/min change. Random 
within-subject variability was added to each true value of each participant in each group so 
that the mean (SD) random variability added was approximately 0 (3) ml/kg/min. These 
errors were Normally distributed. The correlation coefficient between baseline and follow-up 
values was 0.9 for each group. The response threshold was 5 ml/kg/min. This observed 
change is not from the ANCOVA model, i.e. not baseline and control group adjusted. 
 






True baseline mean (SD) 34.8 (7.8) 35.0 (8.2) 35.1 (8.3) 
True follow-up mean (SD) 34.8 (7.8) 38.6 (8.2) 37.1 (8.3) 
True change for all participants 0 3.6 2.0 
Observed baseline mean (SD) 34.8 (8.2) 35.0 (8.8) 35.0 (8.9) 
Observed follow-up mean (SD) 34.7 (8.3) 38.5 (8.8) 37.0 (8.9) 
Observed change (SD)* -0.1 (4.3) 3.5 (4.4) 2.0 (4.3) 
Sample responder counts 
No. of responders 127 363 249 
No. of “adverse” responders 126 27 57 
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Table 2. Number of responders, “uncertain” responders, and adverse responders in 
each of the three study groups according to the individual confidence interval 
approach reported by Bonafiglia et al. (2019). According their approach, the response 
threshold was set at 1 MET (3.5 ml/kg/min). Each individual response interval was calculated 
according to Individual 95% CI = Response estimate ± (1.96 × TE), where TE is SDchange 
in the control group divided by √2 = 4.32/√2 = 3.06. 
 
 Control Group Intervention 1 Intervention 2 
Responders 11 (1.1%) 83 (8.3%) 38 (3.8%) 
Uncertain 974 (97.4%) 916 (91.6%) 957 (95.7%) 
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Table 3. Use of the SDir to estimate the proportion of predicted responders, predicted 
trivial responders, and predicted adverse responders in each of the three populations 
of interest according to the approach reported by Swinton et al. (2018). The proportion 
of responders was estimated as the proportion of a Normal curve above the thresholds of 
3.5 and 5.0 ml/kg/min when the Normal curve has parameters of mean treatment effect 
(from baseline and control group adjusted ANCOVA model) and SD = the “true” SD for 
response heterogeneity.  
Response 
threshold 
Label Intervention 1 
Mean change = 3.6 
SDIR = 0.83 
Intervention 2 
Mean change = 2.2 
SDIR = 0.41 
3.5 ml/min/kg Responders 55% 0% 
Trivial 45% 100% 
Non-responders 0% 0% 
5.0 ml/min/kg Responders 5% 0% 
Trivial 95% 100% 
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